top of page
FTD-GRN IS A GENETICALLY DEFINED DISEASE CHARACTERISED BY REDUCED LEVELS OF PROGRANULIN LEADING TO NEURODEGENERATION, NEUROINFLAMMATION AND DEATH. VESPER BIO’S LEAD ASSET VES001 NORMALISES PROGRANULIN LEVELS BY INTERRUPTING ITS BINDING TO THE MULTIFUNCTIONAL PROTEIN SORTILIN. SORTILIN INHIBITORS ARE BEING INVESTIGATED FOR MUCH MORE THAN NORMALISING PROGRANULIN LEVELS, AND WE HAVE PROGRAMS IN PARKINSON’S DISEASE AND RETINAL NEUROPATHIES.
DISCOVER OUR INNOVATIVE APPROACH TO TACKLING FTD, WITH A FOCUS ON FTD-GRN
SORTILIN
OUR SCIENTIFIC FOUNDERS PIONEERED UNDERSTANDING OF THE ROLE OF THIS MULTIFUNCTIONAL PROTEIN EXPRESSED IN NEURONS AND MICROGLIA. IT BINDS MULTIPLE LIGANDS, INCLUDING PROGRANULIN, PRONEUROTROPHINS, NEUROTENSIN, AND APOB, AND REGULATES THEIR TRAFFICKING AND DEGRADATION.
VESPER BIO TARGETS SORTILIN AT THE CELL SURFACE USING ORAL SMALL MOLECULES AND ANTIBODIES. THIS APPROACH SELECTIVELY DISRUPTS SORTILIN’S PATHOLOGICAL INTERACTION WITH PROGRANULIN, SAFELY RESTORING PROGRANULIN LEVELS WITH THE POTENTIAL TO IMPROVE NEUROINFLAMMATION, REDUCE APOPTOSIS AND IMPROVE LYSOSOMAL FUNCTION.
WE KNOW SORTILIN
OUR SCIENTIFIC ADVISORS
bottom of page